English
简体中文
Total: £ 56.28
Published Date: 2025-10-08 | Pages: 127 | Tables: 116 | Medical Care
The global Molecular Oncology market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.
Molecular diagnostics in cancer is becoming more and more common in clinical laboratories. Targeted therapy possibilities for malignancies such as multiple myeloma, lymphoma, melanoma, lung, breast, ovarian, prostate, and others are now being assessed using molecular oncology assays.Molecular oncology researchers use a variety of methods, including as in-vitro and in vivo functional models, computational biology, genomics, and tumor imaging, to comprehend biological and clinical characteristics.The genes that produce these proteins may be used as targets in the development of novel anti-cancer medications, chemotherapeutic medicines, or imaging scans. These combinatorial methods are used in molecular oncology to confirm the involvement of novel candidate genes in the genesis of cancer.
From a downstream perspective, Hospitals and Clinics accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Molecular Oncology leading manufacturers including Roche Diagnostics, Thermo Fisher Scientific Inc., Illumina, Inc., Qiagen N.V., Agilent Technologies, Inc., Abbott Laboratories, Bio-Rad Laboratories, Inc., Myriad Genetics, Inc., Genomic Health, Inc., etc., dominate supply; the top five capture approximately % of global revenue, with Roche Diagnostics leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Molecular Oncology market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Roche Diagnostics
Thermo Fisher Scientific Inc.
Illumina, Inc.
Qiagen N.V.
Agilent Technologies, Inc.
Abbott Laboratories
Bio-Rad Laboratories, Inc.
Myriad Genetics, Inc.
Genomic Health, Inc.
Segment by Type
PCR
NGS (Next Generation Sequencing)
Microarray
FISH (Fluorescent in situ-hybridization)
Others
Segment by Application
Hospitals and Clinics
Diagnostic Laboratories
Cancer Centers and Specialty Clinics
Others
Sales by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA
Chapter Outline
Chapter 1: Defines the Molecular Oncology study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Introduction to Molecular Oncology: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Molecular Oncology Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 PCR
1.2.3 NGS (Next Generation Sequencing)
1.2.4 Microarray
1.2.5 FISH (Fluorescent in situ-hybridization)
1.2.6 Others
1.3 Market Segmentation by Application
1.3.1 Global Molecular Oncology Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Laboratories
1.3.4 Cancer Centers and Specialty Clinics
1.3.5 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Molecular Oncology Revenue Estimates and Forecasts 2020-2031
2.2 Global Molecular Oncology Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global Molecular Oncology Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global Molecular Oncology Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 PCR Market Size by Players
3.3.2 NGS (Next Generation Sequencing) Market Size by Players
3.3.3 Microarray Market Size by Players
3.3.4 FISH (Fluorescent in situ-hybridization) Market Size by Players
3.3.5 Others Market Size by Players
3.4 Global Molecular Oncology Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Molecular Oncology Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Molecular Oncology Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America Molecular Oncology Market Size by Type (2020-2031)
6.4 North America Molecular Oncology Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Molecular Oncology Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe Molecular Oncology Market Size by Type (2020-2031)
7.4 Europe Molecular Oncology Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Molecular Oncology Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific Molecular Oncology Market Size by Type (2020-2031)
8.4 Asia-Pacific Molecular Oncology Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific Molecular Oncology Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America Molecular Oncology Market Size by Type (2020-2031)
9.4 Central and South America Molecular Oncology Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Molecular Oncology Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa Molecular Oncology Market Size by Type (2020-2031)
10.4 Middle East and Africa Molecular Oncology Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Molecular Oncology Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Roche Diagnostics
11.1.1 Roche Diagnostics Corporation Information
11.1.2 Roche Diagnostics Business Overview
11.1.3 Roche Diagnostics Molecular Oncology Product Features and Attributes
11.1.4 Roche Diagnostics Molecular Oncology Revenue and Gross Margin (2020-2025)
11.1.5 Roche Diagnostics Molecular Oncology Revenue by Product in 2024
11.1.6 Roche Diagnostics Molecular Oncology Revenue by Application in 2024
11.1.7 Roche Diagnostics Molecular Oncology Revenue by Geographic Area in 2024
11.1.8 Roche Diagnostics Molecular Oncology SWOT Analysis
11.1.9 Roche Diagnostics Recent Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Corporation Information
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Molecular Oncology Product Features and Attributes
11.2.4 Thermo Fisher Scientific Inc. Molecular Oncology Revenue and Gross Margin (2020-2025)
11.2.5 Thermo Fisher Scientific Inc. Molecular Oncology Revenue by Product in 2024
11.2.6 Thermo Fisher Scientific Inc. Molecular Oncology Revenue by Application in 2024
11.2.7 Thermo Fisher Scientific Inc. Molecular Oncology Revenue by Geographic Area in 2024
11.2.8 Thermo Fisher Scientific Inc. Molecular Oncology SWOT Analysis
11.2.9 Thermo Fisher Scientific Inc. Recent Developments
11.3 Illumina, Inc.
11.3.1 Illumina, Inc. Corporation Information
11.3.2 Illumina, Inc. Business Overview
11.3.3 Illumina, Inc. Molecular Oncology Product Features and Attributes
11.3.4 Illumina, Inc. Molecular Oncology Revenue and Gross Margin (2020-2025)
11.3.5 Illumina, Inc. Molecular Oncology Revenue by Product in 2024
11.3.6 Illumina, Inc. Molecular Oncology Revenue by Application in 2024
11.3.7 Illumina, Inc. Molecular Oncology Revenue by Geographic Area in 2024
11.3.8 Illumina, Inc. Molecular Oncology SWOT Analysis
11.3.9 Illumina, Inc. Recent Developments
11.4 Qiagen N.V.
11.4.1 Qiagen N.V. Corporation Information
11.4.2 Qiagen N.V. Business Overview
11.4.3 Qiagen N.V. Molecular Oncology Product Features and Attributes
11.4.4 Qiagen N.V. Molecular Oncology Revenue and Gross Margin (2020-2025)
11.4.5 Qiagen N.V. Molecular Oncology Revenue by Product in 2024
11.4.6 Qiagen N.V. Molecular Oncology Revenue by Application in 2024
11.4.7 Qiagen N.V. Molecular Oncology Revenue by Geographic Area in 2024
11.4.8 Qiagen N.V. Molecular Oncology SWOT Analysis
11.4.9 Qiagen N.V. Recent Developments
11.5 Agilent Technologies, Inc.
11.5.1 Agilent Technologies, Inc. Corporation Information
11.5.2 Agilent Technologies, Inc. Business Overview
11.5.3 Agilent Technologies, Inc. Molecular Oncology Product Features and Attributes
11.5.4 Agilent Technologies, Inc. Molecular Oncology Revenue and Gross Margin (2020-2025)
11.5.5 Agilent Technologies, Inc. Molecular Oncology Revenue by Product in 2024
11.5.6 Agilent Technologies, Inc. Molecular Oncology Revenue by Application in 2024
11.5.7 Agilent Technologies, Inc. Molecular Oncology Revenue by Geographic Area in 2024
11.5.8 Agilent Technologies, Inc. Molecular Oncology SWOT Analysis
11.5.9 Agilent Technologies, Inc. Recent Developments
11.6 Abbott Laboratories
11.6.1 Abbott Laboratories Corporation Information
11.6.2 Abbott Laboratories Business Overview
11.6.3 Abbott Laboratories Molecular Oncology Product Features and Attributes
11.6.4 Abbott Laboratories Molecular Oncology Revenue and Gross Margin (2020-2025)
11.6.5 Abbott Laboratories Recent Developments
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Bio-Rad Laboratories, Inc. Corporation Information
11.7.2 Bio-Rad Laboratories, Inc. Business Overview
11.7.3 Bio-Rad Laboratories, Inc. Molecular Oncology Product Features and Attributes
11.7.4 Bio-Rad Laboratories, Inc. Molecular Oncology Revenue and Gross Margin (2020-2025)
11.7.5 Bio-Rad Laboratories, Inc. Recent Developments
11.8 Myriad Genetics, Inc.
11.8.1 Myriad Genetics, Inc. Corporation Information
11.8.2 Myriad Genetics, Inc. Business Overview
11.8.3 Myriad Genetics, Inc. Molecular Oncology Product Features and Attributes
11.8.4 Myriad Genetics, Inc. Molecular Oncology Revenue and Gross Margin (2020-2025)
11.8.5 Myriad Genetics, Inc. Recent Developments
11.9 Genomic Health, Inc.
11.9.1 Genomic Health, Inc. Corporation Information
11.9.2 Genomic Health, Inc. Business Overview
11.9.3 Genomic Health, Inc. Molecular Oncology Product Features and Attributes
11.9.4 Genomic Health, Inc. Molecular Oncology Revenue and Gross Margin (2020-2025)
11.9.5 Genomic Health, Inc. Recent Developments
12 Molecular OncologyIndustry Chain Analysis
12.1 Molecular Oncology Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Molecular Oncology Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Molecular Oncology Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Molecular Oncology Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Molecular Oncology Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Molecular Oncology Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Molecular Oncology Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Molecular Oncology Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global Molecular Oncology Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global Molecular Oncology Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global Molecular Oncology by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Molecular Oncology as of 2024)
Table 11. Global Molecular Oncology Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global Molecular Oncology Companies Headquarters
Table 13. Global Molecular Oncology Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global Molecular Oncology Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global Molecular Oncology Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global Molecular Oncology Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global Molecular Oncology Revenue by Application (2026-2031) & (US$ Million)
Table 21. Molecular Oncology High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America Molecular Oncology Growth Accelerators and Market Barriers
Table 25. North America Molecular Oncology Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe Molecular Oncology Growth Accelerators and Market Barriers
Table 27. Europe Molecular Oncology Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific Molecular Oncology Growth Accelerators and Market Barriers
Table 29. Asia-Pacific Molecular Oncology Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America Molecular Oncology Investment Opportunities and Key Challenges
Table 31. Central and South America Molecular Oncology Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa Molecular Oncology Investment Opportunities and Key Challenges
Table 33. Middle East and Africa Molecular Oncology Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. Roche Diagnostics Corporation Information
Table 35. Roche Diagnostics Description and Major Businesses
Table 36. Roche Diagnostics Product Features and Attributes
Table 37. Roche Diagnostics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. Roche Diagnostics Revenue Proportion by Product in 2024
Table 39. Roche Diagnostics Revenue Proportion by Application in 2024
Table 40. Roche Diagnostics Revenue Proportion by Geographic Area in 2024
Table 41. Roche Diagnostics Molecular Oncology SWOT Analysis
Table 42. Roche Diagnostics Recent Developments
Table 43. Thermo Fisher Scientific Inc. Corporation Information
Table 44. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 45. Thermo Fisher Scientific Inc. Product Features and Attributes
Table 46. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Thermo Fisher Scientific Inc. Revenue Proportion by Product in 2024
Table 48. Thermo Fisher Scientific Inc. Revenue Proportion by Application in 2024
Table 49. Thermo Fisher Scientific Inc. Revenue Proportion by Geographic Area in 2024
Table 50. Thermo Fisher Scientific Inc. Molecular Oncology SWOT Analysis
Table 51. Thermo Fisher Scientific Inc. Recent Developments
Table 52. Illumina, Inc. Corporation Information
Table 53. Illumina, Inc. Description and Major Businesses
Table 54. Illumina, Inc. Product Features and Attributes
Table 55. Illumina, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Illumina, Inc. Revenue Proportion by Product in 2024
Table 57. Illumina, Inc. Revenue Proportion by Application in 2024
Table 58. Illumina, Inc. Revenue Proportion by Geographic Area in 2024
Table 59. Illumina, Inc. Molecular Oncology SWOT Analysis
Table 60. Illumina, Inc. Recent Developments
Table 61. Qiagen N.V. Corporation Information
Table 62. Qiagen N.V. Description and Major Businesses
Table 63. Qiagen N.V. Product Features and Attributes
Table 64. Qiagen N.V. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Qiagen N.V. Revenue Proportion by Product in 2024
Table 66. Qiagen N.V. Revenue Proportion by Application in 2024
Table 67. Qiagen N.V. Revenue Proportion by Geographic Area in 2024
Table 68. Qiagen N.V. Molecular Oncology SWOT Analysis
Table 69. Qiagen N.V. Recent Developments
Table 70. Agilent Technologies, Inc. Corporation Information
Table 71. Agilent Technologies, Inc. Description and Major Businesses
Table 72. Agilent Technologies, Inc. Product Features and Attributes
Table 73. Agilent Technologies, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Agilent Technologies, Inc. Revenue Proportion by Product in 2024
Table 75. Agilent Technologies, Inc. Revenue Proportion by Application in 2024
Table 76. Agilent Technologies, Inc. Revenue Proportion by Geographic Area in 2024
Table 77. Agilent Technologies, Inc. Molecular Oncology SWOT Analysis
Table 78. Agilent Technologies, Inc. Recent Developments
Table 79. Abbott Laboratories Corporation Information
Table 80. Abbott Laboratories Description and Major Businesses
Table 81. Abbott Laboratories Product Features and Attributes
Table 82. Abbott Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Abbott Laboratories Recent Developments
Table 84. Bio-Rad Laboratories, Inc. Corporation Information
Table 85. Bio-Rad Laboratories, Inc. Description and Major Businesses
Table 86. Bio-Rad Laboratories, Inc. Product Features and Attributes
Table 87. Bio-Rad Laboratories, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Bio-Rad Laboratories, Inc. Recent Developments
Table 89. Myriad Genetics, Inc. Corporation Information
Table 90. Myriad Genetics, Inc. Description and Major Businesses
Table 91. Myriad Genetics, Inc. Product Features and Attributes
Table 92. Myriad Genetics, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Myriad Genetics, Inc. Recent Developments
Table 94. Genomic Health, Inc. Corporation Information
Table 95. Genomic Health, Inc. Description and Major Businesses
Table 96. Genomic Health, Inc. Product Features and Attributes
Table 97. Genomic Health, Inc. Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Genomic Health, Inc. Recent Developments
Table 99. Raw Materials Key Suppliers
Table 100. Distributors List
Table 101. Market Trends and Market Evolution
Table 102. Market Drivers and Opportunities
Table 103. Market Challenges, Risks, and Restraints
Table 104. Research Programs/Design for This Report
Table 105. Key Data Information from Secondary Sources
Table 106. Key Data Information from Primary Sources
List of Figures
Figure 1. Molecular Oncology Product Picture
Figure 2. Global Molecular Oncology Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. PCR Product Picture
Figure 4. NGS (Next Generation Sequencing) Product Picture
Figure 5. Microarray Product Picture
Figure 6. FISH (Fluorescent in situ-hybridization) Product Picture
Figure 7. Others Product Picture
Figure 8. Global Molecular Oncology Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 9. Hospitals and Clinics
Figure 10. Diagnostic Laboratories
Figure 11. Cancer Centers and Specialty Clinics
Figure 12. Others
Figure 13. Molecular Oncology Report Years Considered
Figure 14. Global Molecular Oncology Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 16. Global Molecular Oncology Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 17. Global Molecular Oncology Revenue Market Share by Region (2020-2031)
Figure 18. Global Molecular Oncology Revenue Market Share Ranking (2024)
Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 20. PCR Revenue Market Share by Player in 2024
Figure 21. NGS (Next Generation Sequencing) Revenue Market Share by Player in 2024
Figure 22. Microarray Revenue Market Share by Player in 2024
Figure 23. FISH (Fluorescent in situ-hybridization) Revenue Market Share by Player in 2024
Figure 24. Others Revenue Market Share by Player in 2024
Figure 25. Global Molecular Oncology Revenue Market Share by Type (2020-2031)
Figure 26. Global Molecular Oncology Revenue Market Share by Application (2020-2031)
Figure 27. North America Molecular Oncology Revenue YoY (2020-2031) & (US$ Million)
Figure 28. North America Top 5 Players Molecular Oncology Revenue (US$ Million) in 2024
Figure 29. North America Molecular Oncology Revenue (US$ Million) by Type (2020 - 2031)
Figure 30. North America Molecular Oncology Revenue (US$ Million) by Application (2020-2031)
Figure 31. US Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 32. Canada Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 33. Mexico Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 34. Europe Molecular Oncology Revenue YoY (2020-2031) & (US$ Million)
Figure 35. Europe Top 5 Players Molecular Oncology Revenue (US$ Million) in 2024
Figure 36. Europe Molecular Oncology Revenue (US$ Million) by Type (2020-2031)
Figure 37. Europe Molecular Oncology Revenue (US$ Million) by Application (2020-2031)
Figure 38. Germany Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 39. France Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 40. U.K. Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 41. Italy Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 42. Russia Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 43. Asia-Pacific Molecular Oncology Revenue YoY (2020-2031) & (US$ Million)
Figure 44. Asia-Pacific Top 8 Players Molecular Oncology Revenue (US$ Million) in 2024
Figure 45. Asia-Pacific Molecular Oncology Revenue (US$ Million) by Type (2020-2031)
Figure 46. Asia-Pacific Molecular Oncology Revenue (US$ Million) by Application (2020-2031)
Figure 47. Indonesia Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 48. Japan Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 49. South Korea Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 50. Australia Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 51. India Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 52. Indonesia Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 53. Vietnam Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 54. Malaysia Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 55. Philippines Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 56. Singapore Molecular Oncology Revenue (2020-2031) & (US$ Million)
Figure 57. Central and South America Molecular Oncology Revenue YoY (2020-2031) & (US$ Million)
Figure 58. Central and South America Top 5 Players Molecular Oncology Revenue (US$ Million) in 2024
Figure 59. Central and South America Molecular Oncology Revenue (US$ Million) by Type (2020-2031)
Figure 60. Central and South America Molecular Oncology Revenue (US$ Million) by Application (2020-2031)
Figure 61. Brazil Molecular Oncology Revenue (2020-2025) & (US$ Million)
Figure 62. Argentina Molecular Oncology Revenue (2020-2025) & (US$ Million)
Figure 63. Middle East and Africa Molecular Oncology Revenue YoY (2020-2031) & (US$ Million)
Figure 64. Middle East and Africa Top 5 Players Molecular Oncology Revenue (US$ Million) in 2024
Figure 65. South America Molecular Oncology Revenue (US$ Million) by Type (2020-2031)
Figure 66. Middle East and Africa Molecular Oncology Revenue (US$ Million) by Application (2020-2031)
Figure 67. GCC Countries Molecular Oncology Revenue (2020-2025) & (US$ Million)
Figure 68. Israel Molecular Oncology Revenue (2020-2025) & (US$ Million)
Figure 69. Egypt Molecular Oncology Revenue (2020-2025) & (US$ Million)
Figure 70. South Africa Molecular Oncology Revenue (2020-2025) & (US$ Million)
Figure 71. Molecular Oncology Industry Chain Mapping
Figure 72. Channels of Distribution (Direct Vs Distribution)
Figure 73. Bottom-up and Top-down Approaches for This Report
Figure 74. Data Triangulation
Figure 75. Key Executives Interviewed
